Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NPF4
UPID:
OSGEP_HUMAN
Alternative names:
N6-L-threonylcarbamoyladenine synthase; O-sialoglycoprotein endopeptidase; t(6)A37 threonylcarbamoyladenosine biosynthesis protein OSGEP; tRNA threonylcarbamoyladenosine biosynthesis protein OSGEP
Alternative UPACC:
Q9NPF4; Q6IAC3
Background:
The tRNA N6-adenosine threonylcarbamoyltransferase, known by alternative names such as N6-L-threonylcarbamoyladenine synthase and O-sialoglycoprotein endopeptidase, plays a crucial role in the modification of tRNA. This protein is a component of the EKC/KEOPS complex, essential for the formation of a threonylcarbamoyl group on adenosine at position 37 in tRNAs that read codons beginning with adenine. Its activity is vital for the proper translation of genetic information into proteins.
Therapeutic significance:
Given its involvement in Galloway-Mowat syndrome 3, a severe renal-neurological disease, understanding the role of tRNA N6-adenosine threonylcarbamoyltransferase could open doors to potential therapeutic strategies. This protein's function in tRNA modification and its link to developmental and neurological abnormalities highlight its potential as a target for therapeutic intervention.